May 31, 2026

May 2023

FDA advisers vote in favor of Pfizer’s maternal RSV vaccine
Market Watch

FDA advisers vote in favor of Pfizer’s maternal RSV vaccine

Advisers to the U.S. Food and Drug Administration voted Thursday in favor of Pfizer’s PFE, +0.47% respiratory syncytial virus vaccine for pregnant people, following extensive debate about its safety. FDA advisory-committee votes are not binding, but the agency often follows their recommendations. If the FDA ultimately approves the vaccine, called…

Read More